Kevin Zhao, BS, (Yutong_Zhao@dfci.harvard.edu) is helping to investigate mechanisms in tumor proliferation and how they contribute to therapy resistance. He is also involved in studying the efficacy of combinatorial drug therapies with MAPK pathway inhibitors.
Jeffrey Okoro, BA, (JeffreyJ_Okoro@dfci.harvard.edu) aids in elucidating the molecular mechanisms of the KRAS signaling pathway in non-small cell lung cancer (NSCLC). Additionally, he assists in discovering better therapeutic approaches for KRAS mutant lung cancers.
Bo Hee Shin, MA, (BoH_Shin@dfci.harvard.edu) assists in the development of non-conventional approaches to target EGFR, such as highly specific allosteric inhibitors and PROTACs in NSCLC models.
Yoonji Eum, BS, (Yoonji_Eum@DFCI.HARVARD.EDU) is in charge of processing clinical specimens for the establishment of patient-derived lung cancer cell lines, organoids and patient-derived xenografts(PDX). Her projects focus on the biology of mutant EGFR/HER2 NSCLC and the development of HER2-specific targeted therapies.
Timothy Lopez, MS, (Timothy_Lopez@DFCI.HARVARD.EDU) assists in studies focusing on the prevention of resistance to EGFR targeted therapies.